Osteoarthritis (OA) is a major cause of disability, and the risk for developing OA is enhanced by the presence of particular genetic variants. This R21 project will examine how genetic variation is linked to cartilage loss during OA by generating cartilage tissue from stem cells that have been modified to contain the gene variant of interest. The eventual goal is to develop drugs that are specifically matched to patients based on their genetic profile.
